Using blood sampling to test for malaria

Our work

WWARN’s vision is to provide the information necessary to prevent or slow antimalarial drug resistance, in turn, reducing the number of people falling ill and dying from malaria.

The World Health Organization’s Global Plan for Artemisinin Resistance Containment stresses the need to improve the extent and quality of data on malaria drug resistance, fill regional research and data gaps, and strengthen resources to collate available data.

The WorldWide Antimalarial Resistance Network (WWARN)'s mission is to generate innovative tools and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. WWARN works with collaborators to optimise the efficacy of antimalarial medicines and treatment regimens, especially for vulnerable groups including pregnant women, infants and malnourished children, and provides evidence to inform the development of new antimalarial drugs. WWARN also engages and works with other disease research communities to replicate this model for other tropical and neglected diseases.

WWARN provides comprehensive, timely, quality-assured evidence to track the emergence and spread of malaria drug resistance, and improve the efficacy of existing antimalarial medicines and new drugs in development.

Our international partnerships play an essential role in supporting the drive to fight malaria. Through this collaborative approach, the network will continue to provide valuable evidence to help save more lives and support the global effort to control, eliminate and eventually, eradicate malaria.

WWARN is part of the Infectious Diseases Data Observatory (IDDO), a global collaboration that brings together members of the global infectious disease community across the research and humanitarian sectors to collaborate in the generation, analysis and application of data to improve outcomes for patients. 

Structure of WWARN

Our key activities

Assure the quality of antimalarial drug efficacy
  • We provide the malaria community with a reliable and standardised data collection platform to facilitate data sharing and pooled data analyses by WWARN study groups and other research collaborations. These findings provide evidence for policy makers and drug developers to optimise the therapeutic life of existing and new antimalarial drugs
  • We collaborate with laboratories across the world to provide support and advice to improve the analysis of antimalarial drug regimens during clinical trials, and in turn, enhancing the overall quality of the research data captured
Support the international malaria research community
  • We aim to increase awareness and understanding of the need for effective tracking of the emergence and spread of antimalarial resistance
  • We develop strategic partnerships with other advocacy organisations which aim to increase awareness of malaria in the public health and policy making community
  • We raise awareness of the need for data sharing in the public health arena

Publications and brochures

Improving understanding of the impact of poor quality drugs

WWARN Medicine Quality Brochure (PDF, 910 kB)

Proficiency testing and reference standard programmes

WWARN QA/QC Brochure (PDF, 564 kB)

WHO/WWARN guidance document 

With technical support from WWARN, WHO organised an informal consultation resulting in a consensus report: Methods for assessing exposure to antimalarial drugs in clinical field trials (PDF, 6.9 MB)


WWARN is grateful for the generous support we have received from the following organisations: